Baird Medical Secures Indonesian Regulatory Approval for Microwave Ablation Technology
Baird Medical Investment Holdings (NASDAQ: BDMD) has secured regulatory approval from the Indonesian Ministry of Health for its microwave ablation (MWA) technology. The approval covers two key products: the Great Wall Microwave Therapeutic Instrument and the Great Wall Disposable Microwave Ablation Needle.
The company's MWA technology is a minimally invasive procedure that uses targeted microwave energy to destroy abnormal tissue while minimizing impact on surrounding areas. This technology is particularly effective in treating thyroid nodules and tumors, offering benefits such as enhanced precision and faster recovery times.
Following this regulatory milestone, Baird Medical plans to expand its distribution network and collaborate with medical institutions across Indonesia, advancing its global strategic expansion in emerging markets.
Baird Medical Investment Holdings (NASDAQ: BDMD) ha ottenuto l'approvazione normativa dal Ministero della Salute indonesiano per la sua tecnologia di ablazione a microonde (MWA). L'approvazione riguarda due prodotti chiave: lo Strumento Terapeutico a Microonde Great Wall e l'Aguja di Ablazione a Microonde Monouso Great Wall.
La tecnologia MWA dell'azienda è una procedura minimamente invasiva che utilizza energia a microonde mirata per distruggere il tessuto anormale, riducendo al minimo l'impatto sulle aree circostanti. Questa tecnologia è particolarmente efficace nel trattamento di noduli e tumori tiroidei, offrendo vantaggi come una maggiore precisione e tempi di recupero più rapidi.
In seguito a questo traguardo normativo, Baird Medical prevede di espandere la propria rete di distribuzione e collaborare con istituzioni mediche in tutta l'Indonesia, proseguendo la sua espansione strategica globale nei mercati emergenti.
Baird Medical Investment Holdings (NASDAQ: BDMD) ha obtenido la aprobación regulatoria del Ministerio de Salud de Indonesia para su tecnología de ablación por microondas (MWA). La aprobación abarca dos productos clave: el Instrumento Terapéutico de Microondas Great Wall y la Aguja de Ablación por Microondas Desechable Great Wall.
La tecnología MWA de la empresa es un procedimiento mínimamente invasivo que utiliza energía de microondas dirigida para destruir tejido anormal, minimizando el impacto en las áreas circundantes. Esta tecnología es particularmente efectiva en el tratamiento de nódulos y tumores tiroideos, ofreciendo beneficios como mayor precisión y tiempos de recuperación más rápidos.
Tras este hito regulatorio, Baird Medical planea expandir su red de distribución y colaborar con instituciones médicas en toda Indonesia, avanzando en su expansión estratégica global en mercados emergentes.
베어드 메디컬 투자 홀딩스 (NASDAQ: BDMD)는 인도네시아 보건부로부터 마이크로웨이브 절제(MWA) 기술에 대한 규제 승인을 받았습니다. 이 승인에는 두 가지 주요 제품이 포함됩니다: 그레이트 월 마이크로웨이브 치료 기기와 그레이트 월 일회용 마이크로웨이브 절제 바늘.
회사의 MWA 기술은 비침습적인 절차로, 목표 마이크로웨이브 에너지를 사용하여 비정상적인 조직을 파괴하면서 주변 지역에 미치는 영향을 최소화합니다. 이 기술은 갑상선 결절 및 종양 치료에 특히 효과적이며, 향상된 정확성과 빠른 회복 시간과 같은 이점을 제공합니다.
이 규제 이정표 이후, 베어드 메디컬은 배급 네트워크를 확장하고 인도네시아 전역의 의료 기관과 협력할 계획이며, 신흥 시장에서의 글로벌 전략적 확장을 추진하고 있습니다.
Baird Medical Investment Holdings (NASDAQ: BDMD) a obtenu l'approbation réglementaire du ministère de la Santé indonésien pour sa technologie d'ablation par micro-ondes (MWA). L'approbation concerne deux produits clés : l'Instrument Thérapeutique à Micro-ondes Great Wall et l'Aiguille d'Ablation à Micro-ondes Jetable Great Wall.
La technologie MWA de l'entreprise est une procédure peu invasive qui utilise une énergie micro-ondes ciblée pour détruire les tissus anormaux tout en minimisant l'impact sur les zones environnantes. Cette technologie est particulièrement efficace pour traiter les nodules et tumeurs thyroïdiens, offrant des avantages tels qu'une précision accrue et des temps de récupération plus rapides.
Suite à cette étape réglementaire, Baird Medical prévoit d'élargir son réseau de distribution et de collaborer avec des institutions médicales à travers l'Indonésie, faisant avancer son expansion stratégique mondiale sur les marchés émergents.
Baird Medical Investment Holdings (NASDAQ: BDMD) hat die regulatorische Genehmigung des indonesischen Gesundheitsministeriums für seine Mikrowellenablationstechnologie (MWA) erhalten. Die Genehmigung umfasst zwei wichtige Produkte: das Great Wall Mikrowellen-Therapieinstrument und die Great Wall Einweg-Mikrowellenablation-Nadel.
Die MWA-Technologie des Unternehmens ist ein minimalinvasives Verfahren, das gezielte Mikrowellenenergie nutzt, um abnormales Gewebe zu zerstören und gleichzeitig die Auswirkungen auf die umliegenden Bereiche zu minimieren. Diese Technologie ist besonders effektiv bei der Behandlung von Schilddrüsenknoten und -tumoren und bietet Vorteile wie verbesserte Präzision und schnellere Genesungszeiten.
Nach diesem regulatorischen Meilenstein plant Baird Medical, sein Vertriebsnetz auszubauen und mit medizinischen Einrichtungen in ganz Indonesien zusammenzuarbeiten, um seine globale strategische Expansion in Schwellenmärkten voranzutreiben.
- Secured regulatory approval in Indonesia, opening a new market for MWA products
- Expansion into emerging markets strengthens global presence
- Approval covers multiple products, enabling broader market penetration
- None.
"This regulatory approval marks a significant step in our global strategic expansion and underscores our commitment to improving patient care with cutting-edge, minimally invasive technologies," said Haimei Wu, Chairwoman of Baird Medical. "We look forward to collaborating with Indonesian healthcare providers and supporting them with innovative solutions that enhance precision, safety, and patient outcomes.
Microwave ablation is a highly effective, minimally invasive procedure that uses targeted microwave energy to destroy abnormal tissue with minimal impact on surrounding areas. Recognized for its precision and faster recovery times, MWA is widely used for treating conditions such as thyroid nodules and tumors.
With this regulatory milestone, Baird Medical is set to expand its distribution network and collaborate with key medical institutions in
About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in
The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-secures-indonesian-regulatory-approval-for-microwave-ablation-technology-302396592.html
SOURCE BDMD
FAQ
What products did Baird Medical (BDMD) receive approval for in Indonesia?
What medical conditions can Baird Medical's MWA technology treat?
What are the advantages of Baird Medical's microwave ablation technology?
How will the Indonesian regulatory approval impact Baird Medical's business expansion?
